[1]何建华,喻文才.89SrCl2与153Sm-乙二胺四亚甲基膦酸治疗骨转移癌的对比研究[J].国际放射医学核医学杂志,2009,33(2):86-88.[doi:10.3760/cma.j.issn.1673-4114.2009.02.007]
　HE Jian-hua,YU Wen-cai.Comparison of treatment with 89SrCl2 and 153Sm-ethylenediaminetetramethylene phosphate in metastatic cancers of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):86-88.[doi:10.3760/cma.j.issn.1673-4114.2009.02.007]
点击复制

89SrCl2与153Sm-乙二胺四亚甲基膦酸治疗骨转移癌的对比研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
33
期数:
2009年第2期
页码:
86-88
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Comparison of treatment with 89SrCl2 and 153Sm-ethylenediaminetetramethylene phosphate in metastatic cancers of bone
作者:
何建华;  喻文才
重庆市第二人民医院核医学科, 重庆 402160
Author(s):
HE Jian-hua;  YU Wen-cai
Department of Nuclear Medicine, the Second People’s Hospital of Chongqing, Chongqing 402160, China
关键词:
肿瘤转移; 骨肿瘤; 锶放射性同位素; 153Sm-乙二胺四亚甲基膦酸
Keywords:
Neoplasm metastasis; Bone neoplasms; Strontium radioisotopes; 153Sm-ethylene diamihe tetramethylene phosphonic acid
DOI:
10.3760/cma.j.issn.1673-4114.2009.02.007
摘要:
目的 对比研究89SrCl2和153Sm-乙二胺四亚甲基膦酸(153Sm-EDTMP)治疗骨转移癌疗效.方法 120例骨转移患者随机分为89SrCl2治疗组和153Sm-EDTMP治疗组,分别为69例和51例,89SrCl2剂量为1.11~2.22 MBq/Kg,153Sm-EDTMP剂量为25.9~37.0 MBq/kg,3~6月复查SPECT,对止痛效果、转移灶变化及不良反应进行比较分析.结果 89SrCl2组总有效率、显效、有效、无效分别为92.8%、69.6%、23.3%、7.2%;153Sm-EDTMP组的总有效率、显效、有效、无效分别为94.2%、66.7%、27.5%、5.8%,两组比较的差异无统计学意义(χ2=4.98,P>0.05);89SrCl2治疗组骨转移病灶Ⅰ级(变淡,缩小或消失,无新增病灶出现)为56.5%,153Sm-EDTMP组为54.9%,两组比较的差异无统计学意义(χ2=4.81,P>0.05);骨髓抑制情况(白细胞和血小板中任一项降低)分别为40.8%和59.2%,两组比较的差异有统计学意义(χ2=7.45,P<0.05).结论 153Sm-EDTMP和89SrCl2控制乳腺癌、前列腺癌及大多数肺癌骨转移疼痛有效,可根据经济条件选择相应药物.89SrCl2疗效持久,相对骨髓抑制较小,更安全可靠,可作为早期骨转移患者的首选药物.
Abstract:
Objective To evaluate the effect of 89SrCl2 and 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) on metastatic carcinoma of bone. Methods All patients with widespread metastatic bone cancers were divided into two groups randomly:sixty-nine patients were treated with 89SrCl2 with dose of 1.11~2.22 MBq/kg by intravenous injection, fifth-one patients were treated with 153Sm-EDTMP with dose of 25.9~37.0 MBq/kg by the same way. Bone imaging was analized in 3~6 months. The pain, the metastasis varied situation, and side-effect were compared. Results In the group of 89SrCl2 the remission rats of bone pain of positive response, total-effect, apparent, finess, no-effect was 92.8%, 69.6%, 23.3%, 7.2% respectively. In the group of 153Sm-EDTMP, the data were 94.2%, 66.7%, 27.5%, 5.8% respectively. There were not significantly different between groups of 89SrCl2 and 153Sm-EDTMP (χ2=4.98, P>0. 05). In group of 89SrCl2 the rate of area of skeletal metastases Grade Ⅰ (disappear, reduction, maintain and no-new-development) was 56.5%. However it was, in 153Sm-EDTMP group, 54.9%. There was no significantly difference between 89SrCl2 and 153Sm-EDTMP groups (χ2=4.81, P>0.05). The arrest rate of bone marrow (white blood or blood platelet was descended) of 89SrCl2 group was 40.8% while in 153Sm-EDTMP group was 59.2%. There was a significantly different between them (χ2=7.45, P<0.05). Conclusion 89SrCl2 and 153Sm-EDTMP have effect on metastatic carcinoma of bone treatment. It is suggested that one can choose each of them by economic condition. But, 89SrCl2 can maintain the effect in a long time and bone marrow is arrested serious, so it is the first choise for early metastatic carcinoma of bone.

参考文献/References:

[1] Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med, 1999, 26(1):2-7.
[2] 楼岑,张大平,余林良,等.89锶内照射治疗转移性骨肿瘤的临床研究.中华肿瘤杂志,2001,23(6):507-509.
[3] Baczyk M, Czepczynski R, Milecki P, et al. 89Sr versus 151Sm-EDTMP:comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun, 2007, 28(4):245-250.
[4] Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun, 2007, 28(8):623-630.
[5] 路宇,杨志杰.153Sm-EDTMP、89SrCl2治疗前列腺癌、乳腺癌骨转移瘤的对比研究.哈尔滨医科大学学报,2007,41(6):630-631.

相似文献/References:

[1]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
　Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[2]周文兰,吴湖炳,韩彦江,等.18F-FDG PET/CT对骨骼孤立性高代谢病灶的初步诊断价值[J].国际放射医学核医学杂志,2015,39(1):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
　Zhou Wenlan,Wu Hubing,Han Yanjiang,et al.Preliminary study of 18F-FDG PET/CT in the diagnosis of solitary hypermetabolic lesion of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
[3]张胤,陈跃.18F-氟化钠PET/CT诊断肿瘤骨转移应用进展[J].国际放射医学核医学杂志,2015,39(1):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
　Zhang Yin,Chen Yue.Application progress of 18F-NaF PET/CT in the diagnosis of neoplasm metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
[4]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
　Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
[5]刘雪辉,李洪均,于鸿煦.SPECT/CT融合显像对可疑骨转移灶的诊断效能[J].国际放射医学核医学杂志,2015,39(3):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
　Liu Xuehui,Li Hongjun,Yu Hongxu.Diagnostic efficacy of SPECT/CT fusion imaging in assessing possible bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
[6]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
　Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[7]高平,王茜,赵赟赟,等.99Tcm-MDP SPECT/CT显像用于骨肉瘤肺转移的诊断[J].国际放射医学核医学杂志,2014,38(3):148.[doi:10.3760/cma.j.issn.1673-4114.2014.03.002]
　Gao Ping,Wang Qian,Zhao Yunyun,et al.99Tcm-MDP SPECT/CT used in diagnosis of pulmonary metastasis from osteosarcoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):148.[doi:10.3760/cma.j.issn.1673-4114.2014.03.002]
[8]凌彩霞,肖国有.SPECT/CT骨断层显像及在恶性肿瘤骨转移诊断中的临床价值[J].国际放射医学核医学杂志,2014,38(4):275.[doi:10.3760/cma.j.issn.1673-4114.2014.04.016]
　Ling Caixia,Xiao Guoyou.The clinical value of SPECT/CT bone tomography in the diagnosis of malignant tumor metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):275.[doi:10.3760/cma.j.issn.1673-4114.2014.04.016]
[9]王宇峰,刘海娜,张居洋,等.SPECT/CT融合显像对乳腺癌骨转移的诊断价值[J].国际放射医学核医学杂志,2014,38(6):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
　Wang Yu-feng,Liu Hai-na,Zhang Ju-yang,et al.Clinical value of SPECT/CT fusion imaging in diagnosing metastatic bone lesions in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
[10]赵红光,徐松柏,关锋,等.骶骨脊索瘤伴肺转移18F-FDG PET/CT显像一例[J].国际放射医学核医学杂志,2013,37(2):128.[doi:10.3760/cma.j.issn.1673-4114.2013.02.017]
[11]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
　Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
[12]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
　YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[13]叶慧,莫逸,谢爱民,等.18F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究[J].国际放射医学核医学杂志,2008,32(3):147.
　YE Hui,MO Yi,XIE Ai-min,et al.Comparison study of 18F-fluorodeoxyglucose PET-CT and 99Tc-methylene phospho-nate bone scan in detecting bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):147.
[14]郭睿,晋建华,任媛,等.99mTc-枸橼酸盐显像鉴别骨转移癌与良性退行性骨病变[J].国际放射医学核医学杂志,2008,32(3):162.
　GUO Rui,JIN Jian-hua,REN Yuan,et al.Differentiation of malignant and degenerative benign bone disease using 99mTc-citrate scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):162.
[15]耿峻,吴兴勇,胡德胜,等.前列腺癌48例患者全身核素骨显像的临床价值[J].国际放射医学核医学杂志,2007,31(4):238.
[16]青春,邓候富,贾志云.放射性核素89Sr治疗骨转移癌的新进展[J].国际放射医学核医学杂志,2007,31(3):160.
　QING Chun,DENG Hou-fu,JIA Zhi-yun.The new advances of radionuclide 89Sr in metastatic bone cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):160.
[17]王俊起,高硕.PET评价骨转移瘤[J].国际放射医学核医学杂志,2006,30(2):87.
　WANG Jun-qi,GAO Shuo.PET in the evaluation of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):87.

备注/Memo

备注/Memo:
收稿日期:2008-10-11。
通讯作者:何建华(E-mail:jonewelle@sina.com)
更新日期/Last Update: 1900-01-01